Todos Medical

Adding Todos Medical (TODMF) $0.03 to SuperBug Stock Review Watchlist.

Wall Street's War Against SuperBugs. LIVE QUOTE SuperBug Stock Review? Yep, you knew we couldn't resist with all of the CoronaVirus news hitting the tape. Since...
Hapbee

Augmentative Wearable Device, Hapbee, Receives Amazing Reviews by Testers.

Originally posted on MartechSeries. The innovative augmentative wearable device, Hapbee, has been giving testers a reason to be happy. With the ability to allow users...

VirnetX (VHC) Scores $440 Million and Citius Pharma (CTXR) Sees Market Expand to Over...

Internet Stock Review Blast from the past scores big! We added VirnetX (VHC) to the Watch List (Patent Stock Review, since shuttered) back in 2010....
biotech stock review ATXI

Avenue Therapeutics (ATXI) Announces New Drug Application for IV Tramadol Accepted for Review by...

IV tramadol for the management of moderate to moderately severe pain in adults in a medically supervised health care setting. $2.00 to $10 in...

Fortress Bio (FBIO) Inches Closer to $3.00 on Major News.

Fortress Bio (FBIO) Inches Closer to $3.00 on Major News. Citius Pharma (CTXR) Inches Closer to the Next Phase III Data Announcement. Citius Pharma Presenting at...

Video: How Superbugs Get Started.

A World Health Organization (WHO) report released April 2014 stated, "this serious threat is no longer a prediction for the future, it is happening right now...
Citius, Biotech Stock Review

Citius (CTXR) Achieves 50% Patient Enrollment in Phase 3 Mino-Lok® Pivotal Trial

PHASE III PROGRESS October 7th, 2019, Citius Completes 40% - Triggers Data Being Analyzed (is it working?).December 19th, 2019 - Data Analysis Back, Results Positive.February...

Okay, so What’s Next for Citius Pharma (CTXR) $1.16?

Dawson James Broker/Dealer Updates. Price Target Remains at $7.00. "OK, So what’s Next? Topline data from the superior efficacy interim analysis should represent the next...
Citius Pharma

Citius Pharma (CTXR) $1.20. Price Target Upped to $4.00 at HC Wainright.

STREET INSIDER H.C. Wainwright analyst Vernon Bernardino raised the price target on Citius Pharmaceuticals (NASDAQ: CTXR) to $4.00 (from $1.65) while maintaining a Buy rating. The analyst commented,...
coronavirus, biotech stock review

VIDEO: Dyadic (DYAI) CEO Explains What his Industry is Doing to Defeat Coronavirus (FoxNews).

Jan. 27, 2020 - 5:24 - Dyadic International CEO Mark Emalfarb discusses what’s being done to stop the spread of coronavirus and to...

Latest article

Party Time at UniQure (QURE)! From $8.86 to $47.21, up 432%.

I. No Bells, No Baskets.UniQure (QURE) $47 up Huge. Still Not Out Of The Woods!II.Replimune (REPL) $11.23. Gains 28% in Sympathy with UniQure. We...

Adding Bavarian Nordic (BVRNY) $8.91, to Watch List.

Bavarian Nordic Lands $106 Million Contract for its Smallpox/Mpox Vaccine! Were Back for the Third Time! LIVE QUOTE PREVIOUS WRITEUPS Aug 27, 2025: Our 4th Billion Dollar Takeover!...

Fusion Energy Starter.

VC-Funded Fusion Energy Companies "The fastest way to deploy fusion and I believe one of my forecasts is we will replace every coal and natural...